Tandem Diabetes Care, Inc.

TNDM · NASDAQ Global Market · USD

18,71USD

+0,54 (+2,97 %)Stand 10. Nov., 21:00

Vortag 18,17

Kennzahlen

Eröffnung
17,84
Vortag
18,17
Tagesspanne
17,58 – 18,83
52 Wochen
12,26 – 29,65
Volumen
2,72 Mio.
Ø Volumen
2,13 Mio.
Börsenwert
1,31 Mrd. $
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,6
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

CEO
John F. Sheridan
Mitarbeitende
2.500
Hauptsitz
San Diego, CA, US
Sektor
Healthcare
Branche
Medical - Devices
Börsengang
14. Nov. 2013

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.